Global Podiatry Summit 2026

Abstracts

Abstract submission

The Global Podiatry Summit 2026 is scheduled to take place in Copenhagen, Denmark, 12-15 April 2026, at Tivoli Congress Center.

Abstracts must be submitted in English. 

All presenters will be required to attend in-person to make their Oral or Poster Presentations.

  • Abstracts must be submitted online via the abstract submission site. Emails and word processing files submitted outside the abstract submission site will not be accepted.
  • There is no limit to the number of abstracts an author may submit; however, an author may only serve as the presenting author on two submissions.
  • It is the author’s responsibility to designate a new presenter for presentation conflicts that arise.
  • If accepted, the presenter must be an author, or a co-author listed on the abstract at the time of submission.
  • Abstracts must have a complete status by the abstract deadline, or the abstract will not be considered for the program. Extensions will not be granted.

Abstracts are limited to 250 words (excluding references). Please use the Vancouver style for all references. If necessary, the methods section should contain the sex and number of animals or humans included in the study, together with ethical approval information.

The abstract submitter needs to select a category in which their abstract will be considered.

Choose between the following categories:

  • Preventive Podiatry
  • Medical Podiatry
  • Innovation & Technology
  • Practical Clinical Training
  • Abstracts must be written in English.
  • Do not enter author information into the abstract body. Author affiliations will be added automatically based on the information entered during the submission process.
  • Do not include the abstract title or grant support in the abstract body.
  • Standard abbreviations may be used without definition. Nonstandard abbreviations must be placed in parentheses after the first use of the abbreviation.
  • When submitting your abstract, the Abstract Scientific Committee recommends using language that is neutral, nonjudgmental, and free from stigma.
  • Proofread abstracts carefully to avoid errors. Modifications will not be allowed after the January 20, 2026, deadline.
  • Note: The Abstract Scientific Committee may modify the format to fit the look and feel of the media on which it is displayed or distributed.

All abstracts successfully submitted are reviewed by the Abstract Scientific Committee.

Originality of work, adequacy of data, and clarity of exposition are the determinants in the selection of abstracts. An abstract that does not present the results of the study will not be considered for oral communication but may be eligible for a poster presentation.

The final decision with respect to the selection and programming of any abstract will be made by the Abstract Scientific Committee.

Abstracts may be selected for oral presentation or poster presentation, or not selected.

Abstract acceptance status will be sent via email to the designated presenting author on February 13.

Abstract presenters will be required to attend Global Podiatry Summit 2026 in-person to make their presentation. Expenses associated with an abstract presentation (e.g., travel, hotel, congress registration fees, etc.) are the sole responsibility of the presenting author.

Presenters must register for the symposium before the abstract submission deadline of January 20, 2026 to be considered for presentation at the symposium. Abstracts that are not accompanied by an author registration will not be part of the abstract review & selection.

Abstract submission opens:
-

SUBMISSION DEADLINE:
20 January 2026, 23:59 CEST

Abstract notification:
13 February 2026

TEKST

Information

ISCU is a recently established member organization which aims to promote the use of high frequency and ultra-high frequency ultrasonography (HFUS and UHFUS) in dermatology. 

The aim of ISCU is to develop a multidisciplinary international network to disseminate the knowledge on the ultrasonographic study of skin and subcutaneous tissue, to better understand the evolution of skin diseases from early to advanced stages, allowing early diagnoses and correct ultrasound-guided treatments. Bridging the gap between diagnosing and treatment to exploit the potential of implementing ultrasound techniques for skin.